Peter Wipfler

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment

Peter Wipfler, Katrin Oppermann, Georg Pilz et al. · Multiple Sclerosis Journal · 2010 · 37 citations

COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry

Gabriel Bsteh, Hamid Assar, Harald Hegen et al. · PLoS ONE · 2021 · 34 citations · Full text

Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells

Andrea Harrer, Peter Wipfler, Max Einhaeupl et al. · Journal of Neuroimmunology · 2011 · 32 citations

Natalizumab Therapy, Novel Therapy, Malignant Blood Disorder +10

Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction

Georg Pilz, Irma Sakic, Peter Wipfler et al. · Fluids and Barriers of the CNS · 2020 · 31 citations · Full text

The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF

Christine Harrer, Ferdinand Otto, Georg Pilz et al. · Fluids and Barriers of the CNS · 2021 · 30 citations · Full text